false 0000921114 0000921114 2024-06-12 2024-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 12, 2024

 

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

 

Washington   001-37544   91-1549568
(State or other jurisdiction
of incorporation or organization)		   (Commission File Number)   (IRS Employer Identification No.)

 

5005 McConnell Avenue
 Los Angeles, California		   90066
(Address of principal executive offices)   (Zip Code)

 

(310) 655-2928

(Registrant’s Telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which
Registered
Common Stock   ARMP   NYSE American

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

At the Annual Meeting of Shareholders held on June 12, 2024 (the “Meeting”), the shareholders of the Company elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2025, as follows:

 

Members  Number of
Shares Voted
For		  Number of
Shares
Withheld		  Broker Non-
Votes
Deborah L. Birx, M.D.  30,016,901  199,470  1,351,031
Jules Haimovitz  30,028,176  188,195  1,351,031
Odysseas D. Kostas, M.D.  29,393,679  822,692  1,351,031
Robin C. Kramer  30,083,215  133,156  1,351,031
Joseph M. Patti, Ph. D.  30,061,888  154,483  1,351,031
Todd C. Peterson, Ph. D.  30,069,000  147,371  1,351,031
Sarah Schlesinger, M.D.  29,393,400  822,971  1,351,031

 

At the Meeting, our shareholders next approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The vote for such approval was 30,142,693 shares for, 55,393 shares against, 18,285 shares abstaining, and 1,351,031 shares of broker non-votes.

 

Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. The vote for such ratification was 31,543,360 shares for, 20,716 shares against, 3,326 shares abstaining, and 0 shares of broker non-votes.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 14, 2024 Armata Pharmaceuticals, Inc.
   
  By: /s/ Richard Rychlik
  Name: Richard Rychlik
  Title: Principal Financial Officer and Corporate Controller

 

-2-

 

v3.24.1.1.u2
Cover
Jun. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 12, 2024
Entity File Number 001-37544
Entity Registrant Name ARMATA PHARMACEUTICALS, INC.
Entity Central Index Key 0000921114
Entity Tax Identification Number 91-1549568
Entity Incorporation, State or Country Code WA
Entity Address, Address Line One 5005 McConnell Avenue
Entity Address, City or Town Los Angeles
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90066
City Area Code 310
Local Phone Number 655-2928
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ARMP
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Armata Pharmaceuticals (AMEX:ARMP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Armata Pharmaceuticals.
Armata Pharmaceuticals (AMEX:ARMP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Armata Pharmaceuticals.